Europe

Brexit Likely to Cause Talent Shortage for Biopharma in the UK
Brexit Likely to Cause Talent Shortage for Biopharma in the UK
BioSpace
UK
Europe
Brexit
Flag link:
U.K. Could Be Kicked Out Of Newly Launched Pharma Tech Security System Because Of Brexit
U.K. Could Be Kicked Out Of Newly Launched Pharma Tech Security System Because Of Brexit
Forbes
Europe
UK
Brexit
Falsified Medicines Directive
security
Flag link:
AZ’s lung drug gets fast development in EU and US
AZ’s lung drug gets fast development in EU and US
Pharmaforum
AstraZeneca
MEDI8897
RSV
Europe
fast track
Flag link:
Oncology round-up: CAR-T conference raises hopes for solid tumour therapy
Oncology round-up: CAR-T conference raises hopes for solid tumour therapy
Pharmaforum
CAR-T
CAR-T Congress
oncology
Novartis
Kymriah
Europe
Flag link:
Brexit could hinder CAR-T reimbursement in Europe
Brexit could hinder CAR-T reimbursement in Europe
Pharmaforum
Brexit
UK
Europe
CAR-T
Flag link:
Estonia Houses The Biggest Biobank In Europe
Estonia Houses The Biggest Biobank In Europe
Forbes
Europe
biotech
Estonia
biobank
Flag link:
Biopharma Companies Explain Brexit Preparations
Biopharma Companies Explain Brexit Preparations
RAPS.org
Brexit
UK
Europe
drug shortages
Flag link:
Novartis urges Britain to secure drug supplies before Brexit
Novartis urges Britain to secure drug supplies before Brexit
Yahoo/Reuters
Novartis
UK
Brexit
Europe
drug shortages
Flag link:
25 European medtech and life sciences start-ups to watch in 2019
25 European medtech and life sciences start-ups to watch in 2019
Silicon Republic
Europe
devices
startups
ADA
Ava
Aiforia
Bambi Medical
BioBeats
BrainWave Bank
Diaceutics
Dobco Medical Systems
Doctena
Etsimo
Fluidic Analytics
Heartbeat Medical
HealthBeacon
Healthera
Healx
Kite Medical
Medherant
Neurent Medical
Nuritas
Oura
Sword Health
UgenTec
WhiteSwell
Ultromics
Xeltis
Flag link:
The Biotech VC View: What Does 2019 Hold For European Health Startups?
The Biotech VC View: What Does 2019 Hold For European Health Startups?
Forbes
Europe
biotech
venture capital
Flag link:
Brexit and beyond: the challenges ahead for pharma
Brexit and beyond: the challenges ahead for pharma
Pharmaforum
Brexit
UK
Europe
Flag link:
European Commission Approves Janssen's Erleada for Patients at High Risk of Developing Metastatic Prostate Cancer
European Commission Approves Janssen's Erleada for Patients at High Risk of Developing Metastatic Prostate Cancer
CP Wire
Janssen
JNJ
Erleada
prostate cancer
Europe
Flag link:
As Brexit nears, EMA improves staff retention forecast, commits to uninterrupted drug evaluations
As Brexit nears, EMA improves staff retention forecast, commits to uninterrupted drug evaluations
Fierce Biotech
EMA
Europe
Brexit
UK
Amsterdam
Flag link:
US loses, EU wins as Chinese biotech investment shifts focus
US loses, EU wins as Chinese biotech investment shifts focus
Pharmaforum
China
Europe
biotech
Flag link:
Why The U.S. Remains The World’s Most Expensive Market For ‘Biologic’ Drugs
Why The U.S. Remains The World’s Most Expensive Market For ‘Biologic’ Drugs
KHN
biologics
United States
Europe
Flag link:
Merck bags adjuvant okay for Keytruda in melanoma
Merck bags adjuvant okay for Keytruda in melanoma
Pharmaforum
Merck
Europe
Keytruda
melanoma
Flag link:
The Great Pharma Brexit? An Endpoints News snap poll finds most life sciences insiders predicting a debacle for the industry
The Great Pharma Brexit? An Endpoints News snap poll finds most life sciences insiders predicting a debacle for the industry
Endpoints
pharma industry
UK
Europe
Brexit
Flag link:
Clovis Oncology Prevails in European Patent Proceedings Related to Rubraca
Clovis Oncology Prevails in European Patent Proceedings Related to Rubraca
CP Wire
Clovis Oncology
Europe
Rubraca
Flag link:
How Pharmaceuticals Impact the Environment: EMA Revises Guideline
How Pharmaceuticals Impact the Environment: EMA Revises Guideline
RAPS.org
Europe
EMA
environmental concerns
Flag link:
Novartis’ Gilenya gets approval in Europe to treat children and adolescents with MS
Novartis’ Gilenya gets approval in Europe to treat children and adolescents with MS
Pharmaceutical Business Review
Novartis
Gilenya
Europe
Relapsing Remitting Multiple Sclerosis
Flag link:

Pages